Oncimmune CEO discusses latest large antibody research contract and profitability goals

Oncimmune Holdings PLC CEO Martin Gouldstone discusses the company's recent achievements, including a new $700,000 contract with a major pharmaceutical company. This contract follows a significant $1.5 million deal announced in May 2024. Gouldstone emphasised the growing commercial traction of Oncimmune's profiling autoantibodies technology, particularly in diseases affecting the immune system. During the interview, Gouldstone discussed the company’s pipeline and the importance of these contracts as indicators of Oncimmune's progress. "Contracts like these give us a lot of confidence that we can meet our full year 2024 targets and achieve profitability in full year 2025," said Gouldstone. He also highlighted the company's strategy to expand its commercial team, particularly in the US market. With these significant wins, Oncimmune is on track to reach profitability for the first time in its history, marking a major milestone for the company. Stay tuned to learn more about Oncimmune's ongoing developments and future announcements. Visit Proactive’s YouTube channel for more videos, and don't forget to give this video a like, subscribe to the channel, and enable notifications for future content. #Oncimmune #Pharmaceuticals #Autoantibodies #Biotech #HealthcareInnovation #MartinGouldstone #BiotechInvesting #CommercialStrategy #USMarket #ProactiveInvestors #Oncimmune #Pharmaceuticals #Autoantibodies #Biotech #HealthcareInnovation #MartinGouldstone #BiotechInvesting #CommercialStrategy #USMarket #ProactiveInvestors